A stem cell transplant for leukemia replaces a patient’s diseased bone marrow with healthy blood-forming stem cells, usually from a donor. It is used when leukemia is unlikely to be cured by chemotherapy alone, such as high-risk acute myeloid leukemia, relapsed acute lymphoblastic leukemia, or chronic leukemias that no longer respond to drugs. Its power comes from two effects: intensive treatment before the transplant, and the donor immune system attacking any remaining leukemia cells.
I am often asked who needs a transplant, how a donor is found, and what the months afterward look like. This guide answers those questions in plain language.
What Is a Stem Cell Transplant?
Stem cell transplant, also called hematopoietic stem cell transplantation (HSCT), gives a patient new hematopoietic stem cells. These are the parent cells in the bone marrow that make red blood cells, white blood cells, and platelets. After the transplant, they settle in the marrow and rebuild the blood and immune system.
“Bone marrow transplant” and “stem cell transplant” are often used interchangeably. The difference mainly lies in where the cells are collected from, which is covered in our article on bone marrow transplant vs stem cell transplant.
Autologous vs allogeneic transplant
There are two main types. An autologous transplant uses the patient’s own stem cells, collected and frozen before high-dose treatment. An allogeneic transplant uses cells from a donor whose tissue type (HLA) is a close match.
For leukemia, allogeneic transplant is far more common. Leukemia starts in the marrow itself, so the patient’s own cells risk carrying the disease back in. A donor’s immune cells also provide the graft-versus-leukemia effect, in which donor T cells recognize and destroy leftover leukemia cells. Autologous transplant is used much more often for myeloma and lymphoma.
| Feature | Autologous | Allogeneic |
|---|---|---|
| Source of cells | Patient’s own | Matched donor |
| Graft-versus-leukemia effect | No | Yes |
| Graft-versus-host disease risk | None | Yes |
| Risk of reinfusing leukemia cells | Present | None |
| Main role in leukemia | Limited | Standard curative transplant |
Who Needs a Transplant for Leukemia?
Not everyone with leukemia needs a transplant. The decision depends on the type of leukemia, its genetic features, how well it responded to initial treatment, and the patient’s overall fitness. Common situations include:
- Acute myeloid leukemia (AML): in first remission when genetic risk is intermediate or adverse, or after relapse
- Acute lymphoblastic leukemia (ALL): high-risk features, persistent measurable residual disease (MRD) after treatment, or relapse
- Chronic myeloid leukemia (CML): resistance to tyrosine kinase inhibitors or progression to blast phase
- Chronic lymphocytic leukemia (CLL): rarely, for high-risk disease that has failed multiple modern therapies
Leukemia arises from genetic changes in immature marrow cells, and these changes shape both risk and the case for transplant. Risk factors such as prior chemotherapy or radiation, benzene exposure, and certain inherited conditions like Down syndrome can also point toward higher-risk disease.
Diagnosis and Pre-Transplant Workup
Leukemia usually presents with fatigue, infections, easy bruising or bleeding, and sometimes weight loss, reflecting the crowding out of normal blood production. These overlap with many other hematological conditions, so testing is essential.
A complete blood count is the first step, followed by bone marrow aspiration and biopsy with flow cytometry, cytogenetics, and molecular testing. These results define the subtype and risk group, which in turn determine whether transplant is recommended.
Before transplant, the team checks heart, lung, kidney, and liver function, screens for infections, and confirms the leukemia is in remission where possible. HLA typing of the patient and potential donors begins early, often at diagnosis for high-risk cases.
Donors and the Transplant Process
Finding a donor
Each full sibling has a 1 in 4 chance of being an HLA match. If no sibling matches, the options are:
- Matched unrelated donor found through a volunteer registry
- Haploidentical donor, a half-matched parent, child, or sibling
- Umbilical cord blood, which tolerates less strict matching
Stem cells are usually collected from the donor’s bloodstream after growth-factor injections move them out of the marrow. Less often, they are harvested directly from the donor’s hip bones under anesthesia.
The transplant process step by step
| Stage | Typical timing | What happens |
|---|---|---|
| Conditioning | About one week before day 0 | Chemotherapy, sometimes with radiation, to destroy leukemia and suppress immunity |
| Infusion (day 0) | One day | Stem cells given through a central line, like a transfusion |
| Engraftment | Usually 2 to 4 weeks | New cells begin making blood; transfusions and infection prevention continue |
| Early recovery | First 100 days | Close monitoring for GVHD, infections, and organ problems |
| Long-term recovery | Months to years | Immune rebuilding, revaccination, late-effect screening |
Myeloablative conditioning uses high doses to wipe out the marrow and is suited to younger, fitter patients. Reduced-intensity conditioning relies more on the graft-versus-leukemia effect and allows older patients or those with other health problems to undergo transplant.
Risks and Complications
- Infections while blood counts and immunity are low, including bacterial, fungal, and viral infections
- Graft-versus-host disease (GVHD), where donor immune cells attack the patient’s skin, gut, liver, or other organs; it can be acute or chronic
- Relapse of leukemia, which remains a leading cause of transplant failure
- Sinusoidal obstruction syndrome, a liver complication of conditioning
- Graft failure, infertility, and long-term effects on the heart, lungs, and hormones
Treatments such as post-transplant cyclophosphamide, better antiviral and antifungal drugs, and MRD monitoring have made transplant safer and more widely available than in the past.
Key Takeaways
- A stem cell transplant for leukemia replaces diseased marrow with healthy stem cells, usually from a matched donor.
- Allogeneic transplant is the standard approach because of the graft-versus-leukemia effect.
- It is reserved for higher-risk or relapsed leukemia, guided by genetics and response to treatment.
- Siblings, unrelated volunteers, half-matched relatives, and cord blood can all serve as donors.
- Infection, GVHD, and relapse are the main risks, and recovery takes months.
Frequently Asked Questions
Can a stem cell transplant cure leukemia?
For many patients, yes. Allogeneic transplant offers a chance of long-term cure in leukemias that chemotherapy alone is unlikely to eliminate. The chance depends on the leukemia type, remission status, and overall health.
How long is the hospital stay?
Most allogeneic transplant patients stay in hospital for several weeks, until their counts recover. Close outpatient follow-up continues for months, and patients usually need to stay near the transplant center for the first 100 days.
Is donating stem cells painful?
Blood stem cell collection is similar to a long blood donation, and the growth-factor injections can cause bone aches. Marrow harvest is done under anesthesia and leaves the hips sore for a few days.
What happens if leukemia comes back after transplant?
Options include stopping immunosuppression, giving donor lymphocyte infusions, targeted drugs, or in selected cases a second transplant. The best choice depends on timing and the leukemia’s features.
For more on leukemia types and treatments, see our leukemia guide.
